Interpreting the Efficacy of Liposomal Bupivacaine in Fascial Plane Blocks for Elderly Patients: A Methodological Reappraisal [Letter] Authors: Hongyu Gai, Ying Hou, Yang Yu Published: 2026 Dear editor We read with interest the randomized controlled trial by Gu et al1 comparing liposomal bupivacaine (LB) versus plain bupivacaine (BP) versus no block for transversus abdominis plane + rectus sheath block (TAP+RSB) in elderly patients undergoing laparoscopic inguinal hernia repair. The authors conclude that LB provides superior opioid‑sparing and accelerated recovery. While the study addresses an important clinical question, several methodological concerns warrant careful discussion. First, the sample‑size calculation appears to have been designed only to detect the presence of any block (active versus control), not a difference between LB and BP. The authors assumed mean 48‑hour morphine‑equivalent consumption of 30 mg in the control group and 20 mg in both active groups, then calculated 47 patients per group. With this assumption, the study was adequately powered to show that TAP+RSB reduces opioid use compared with no block, but it was not powered to test LB against BP. Indeed, the actual difference between LB and BP was only –1.71 mg (95% CI –4.30 to 0.88, P = 0.401). Given the wide confidence interval and the low power for this contrast, the repeated statements that LB is “particularly” effective or “especially” beneficial relative to BP are not supported by the data. For multi‑arm trials, sample size should be estimated for each pairwise comparison of interest, especially when superiority of one active agent is claimed.2,3 Second, the use of LB for TAP and rectus sheath blocks is not currently included in the approved indications according to the product label.4 While off‑label use is not prohibited in clinical research, we believe it is important for readers to be aware of this regulatory context. The authors did not disclose whether the institutional review board specifically reviewed this off‑label application or whether patients were informed of this fact. Transparency regarding off‑label use is particularly relevant when interpreting the safety and generalisability of the findings, as the pharmacokinetic profile and local tissue effects of LB in fascial planes have not been extensively studied.5 We would encourage the authors to provide this information. Third, we noted several data‑integrity issues that raise concerns about the reliability of the results. In Table 4,1 the bleeding volume for the control group is listed as “50.635” without units or standard deviation, whereas the LB and BP groups show 5.00 (5.00, 5.00). This appears to be a typographical error, but it suggests that data entry and verification may not have been sufficiently rigorous.6 More importantly, surgical duration differed significantly across groups (LB 44 min, control 34 min; P = 0.017), indicating possible failure of randomisation or unblinded anaesthesiologist bias. Although the authors performed a post‑hoc adjustment for surgical time, this analysis was not prespecified in the trial protocol (ChiCTR2400086990). Such data‑driven adjustments can introduce bias and should be clearly labelled as exploratory rather than confirmatory.7,8 Fourth, several secondary outcomes specified in the Methods—Steward score, Ramsay Sedation Scale-are entirely absent from the Results. MMSE data are reported only as change scores without the actual incidence of postoperative cognitive dysfunction, which is particularly relevant for elderly patients. This selective reporting undermines the completeness of the recovery assessment and may affect the interpretation of the safety profile.9 In summary, while the study demonstrates that TAP+RSB reduces opioid consumption compared with no block-a finding consistent with existing literature-the claim that LB is superior to plain bupivacaine is not supported by the statistical design, involves off‑label use not disclosed to readers, and is accompanied by data inconsistencies and selective outcome reporting. We would encourage the authors to provide raw data for independent reanalysis, clarify the regulatory and ethical approvals for LB use in TAP/RSB, and revise the conclusion to reflect the actual evidence. Disclosure The authors report no conflicts of interest in this communication. References